• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

常见类型肺癌的非典型组织病理学特征——我们的经验与文献回顾。

Atypical Histopathological Aspects of Common Types of Lung Cancer-Our Experience and Literature Review.

机构信息

Research Department, "Marius Nasta" Institute of Pneumophthisiology, 050159 Bucharest, Romania.

Pathology Department, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.

出版信息

Medicina (Kaunas). 2024 Jan 7;60(1):112. doi: 10.3390/medicina60010112.

DOI:10.3390/medicina60010112
PMID:38256374
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10818882/
Abstract

Lung cancer is among the most common oncological diseases regarding incidence and mortality, with most of these having epithelial origins. Pathological reporting of these tumors is conducted according to the 5th edition of the World Health Organisation (WHO) classification of thoracic tumours. This study aims to draw the pathologist's attention to four rare, atypical microscopic aspects that some of the most common types of lung malignancies reveal upon standard evaluation (hematoxylin-eosin stain) that make histopathological diagnosis challenging: acantholytic, pseudoangiosarcomatous, signet ring cell, and clear cell features. Each of these aspects was exemplified by a case diagnosed in the pathology department of the "Marius Nasta" Institute. Furthermore, we analyzed the classification dynamics of different WHO editions and used PubMed to review articles written in English and published in the last eleven years on this subject. Pathologists should be familiar with these unusual aspects to avoid misdiagnoses and to ensure the correct classification of tumors, which is extremely important because these tumor phenotypes have been associated with specific molecular alterations and a worse clinical evolution. There is a need to clarify the histogenesis and associated genetic mutations, given the fact that the rarity of these tumor phenotypes makes their study difficult. Some authors consider these to be overlapping entities; however, we do not encourage this, as they may exhibit different prognoses and various molecular alterations with important therapeutic implications. The signet ring cell feature was associated with ALK rearrangement in lung adenocarcinoma; thus, these patients can benefit from tailored therapy with ALK-tyrosine kinase inhibitors (ALK-TKI). Recent studies associated clear cell morphology with FGFR3-TACC3 fusion, suggesting that patients with this diagnosis may be potentially eligible for FGFR inhibitors. We described, for the first time, the pseudoangiosarcomatous pattern in a case of lung adenocarcinoma; to our knowledge this aspect has only been described until now in the context of squamous cell carcinomas.

摘要

肺癌是发病率和死亡率最高的常见肿瘤之一,其中大多数起源于上皮细胞。这些肿瘤的病理报告是根据世界卫生组织(WHO)第 5 版胸部肿瘤分类进行的。本研究旨在提请病理学家注意四种罕见的、非典型的微观方面,一些最常见的肺癌恶性肿瘤在标准评估(苏木精-伊红染色)中揭示了这些方面,使得组织病理学诊断具有挑战性:棘层松解、假性血管肉瘤样、印戒细胞和透明细胞特征。每个方面都通过在“Marius Nasta”研究所的病理科诊断的一个病例进行了例证。此外,我们分析了不同 WHO 版本的分类动态,并使用 PubMed 回顾了过去十一年间就该主题发表的英文文章。病理学家应该熟悉这些不寻常的方面,以避免误诊并确保肿瘤的正确分类,这一点非常重要,因为这些肿瘤表型与特定的分子改变和更差的临床转归有关。鉴于这些肿瘤表型的罕见性,需要阐明其组织发生和相关的基因突变。一些作者认为这些是重叠的实体;然而,我们不鼓励这样做,因为它们可能表现出不同的预后和各种具有重要治疗意义的分子改变。肺腺癌中的印戒细胞特征与 ALK 重排相关;因此,这些患者可以受益于针对 ALK 酪氨酸激酶抑制剂(ALK-TKI)的靶向治疗。最近的研究将透明细胞形态与 FGFR3-TACC3 融合相关联,提示具有这种诊断的患者可能有资格接受 FGFR 抑制剂治疗。我们首次描述了肺腺癌中假性血管肉瘤样模式;据我们所知,到目前为止,这种方面仅在鳞状细胞癌中有所描述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/b606af93deca/medicina-60-00112-g021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/090f6f985e68/medicina-60-00112-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/7d4acd384c5c/medicina-60-00112-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/4983e4095463/medicina-60-00112-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/33127e1fa588/medicina-60-00112-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/4ead01bd7813/medicina-60-00112-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/5f391d354dc8/medicina-60-00112-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/92f8b8fc600f/medicina-60-00112-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/2bee05b58c52/medicina-60-00112-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/e89a64f08e57/medicina-60-00112-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/90085f1fc9e9/medicina-60-00112-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/b5d00d3991b7/medicina-60-00112-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/978606527ebb/medicina-60-00112-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/0cf1616dc939/medicina-60-00112-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/439884b4b351/medicina-60-00112-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/33c52118a328/medicina-60-00112-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/48b7708b9677/medicina-60-00112-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/50873e9331e3/medicina-60-00112-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/ccd1dd984ac4/medicina-60-00112-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/8d11b0294a82/medicina-60-00112-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/73fc0112af48/medicina-60-00112-g020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/b606af93deca/medicina-60-00112-g021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/090f6f985e68/medicina-60-00112-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/7d4acd384c5c/medicina-60-00112-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/4983e4095463/medicina-60-00112-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/33127e1fa588/medicina-60-00112-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/4ead01bd7813/medicina-60-00112-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/5f391d354dc8/medicina-60-00112-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/92f8b8fc600f/medicina-60-00112-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/2bee05b58c52/medicina-60-00112-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/e89a64f08e57/medicina-60-00112-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/90085f1fc9e9/medicina-60-00112-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/b5d00d3991b7/medicina-60-00112-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/978606527ebb/medicina-60-00112-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/0cf1616dc939/medicina-60-00112-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/439884b4b351/medicina-60-00112-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/33c52118a328/medicina-60-00112-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/48b7708b9677/medicina-60-00112-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/50873e9331e3/medicina-60-00112-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/ccd1dd984ac4/medicina-60-00112-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/8d11b0294a82/medicina-60-00112-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/73fc0112af48/medicina-60-00112-g020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec2/10818882/b606af93deca/medicina-60-00112-g021.jpg

相似文献

1
Atypical Histopathological Aspects of Common Types of Lung Cancer-Our Experience and Literature Review.常见类型肺癌的非典型组织病理学特征——我们的经验与文献回顾。
Medicina (Kaunas). 2024 Jan 7;60(1):112. doi: 10.3390/medicina60010112.
2
Cytomorphological features of ALK-positive lung adenocarcinomas: psammoma bodies and signet ring cells.ALK 阳性肺腺癌的细胞形态学特征:砂粒体和印戒细胞。
Cancer Cytopathol. 2015 Mar;123(3):162-70. doi: 10.1002/cncy.21507. Epub 2014 Dec 29.
3
ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma.ALK 易位与原发性肺腺癌中的 ALK 免疫反应性和广泛的印戒细胞形态有关。
Lung Cancer. 2012 Mar;75(3):300-5. doi: 10.1016/j.lungcan.2011.07.017. Epub 2011 Aug 19.
4
Non-Small Cell Lung Carcinoma With Clear Cell Features and FGFR3::TACC3 Gene Rearrangement : Clinicopathologic and Next Generation Sequencing Study of 7 Cases.非小细胞肺癌伴透明细胞特征和 FGFR3::TACC3 基因重排:7 例的临床病理和下一代测序研究。
Am J Surg Pathol. 2024 Mar 1;48(3):284-291. doi: 10.1097/PAS.0000000000002167. Epub 2023 Dec 12.
5
Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas.ALK 重排肺腺癌的组织学和细胞学特征。
Mod Pathol. 2012 Nov;25(11):1462-72. doi: 10.1038/modpathol.2012.109. Epub 2012 Jun 29.
6
Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component.肺腺癌伴印戒细胞成分中频繁的 ALK 重排和 TTF-1/p63 共表达。
Lung Cancer. 2011 Jun;72(3):309-15. doi: 10.1016/j.lungcan.2010.09.013. Epub 2010 Oct 30.
7
Prominent Signet Ring Cell Morphology in a Pulmonary Squamous Cell Carcinoma.肺鳞状细胞癌中显著的印戒细胞形态。
Turk Patoloji Derg. 2018;34(2):194-197. doi: 10.5146/tjpath.2015.01337.
8
ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?对克唑替尼有反应的ALK重排鳞状细胞肺癌:非小细胞肺癌领域中缺失的环节?
Lung Cancer. 2016 Jan;91:67-9. doi: 10.1016/j.lungcan.2015.11.010. Epub 2015 Nov 10.
9
ALK rearrangement in specific subtypes of lung adenocarcinoma: immunophenotypic and morphological features.肺腺癌特定亚型中的ALK重排:免疫表型和形态学特征
Med Oncol. 2017 May;34(5):76. doi: 10.1007/s12032-017-0936-z. Epub 2017 Mar 31.
10
Leptomeningeal carcinomatosis as initial presentation in adenocarcinoma of lung with signet ring cell features: an autopsy case report.以脑膜癌病为首发表现的具有印戒细胞特征的肺腺癌:一例尸检病例报告
Int J Clin Exp Pathol. 2012;5(9):972-6. Epub 2012 Oct 20.

引用本文的文献

1
How Morphology Shapes Survival in Invasive Squamous Cell Carcinoma of the Lung.形态学如何影响肺浸润性鳞状细胞癌的生存
Diagnostics (Basel). 2024 Oct 11;14(20):2264. doi: 10.3390/diagnostics14202264.
2
Correlation between Radiological Characteristics, PET-CT and Histological Subtypes of Primary Lung Adenocarcinoma-A 102 Case Series Analysis.原发性肺腺癌的放射学特征、PET-CT与组织学亚型之间的相关性——102例病例系列分析
Medicina (Kaunas). 2024 Apr 10;60(4):617. doi: 10.3390/medicina60040617.

本文引用的文献

1
Non-Small Cell Lung Carcinoma With Clear Cell Features and FGFR3::TACC3 Gene Rearrangement : Clinicopathologic and Next Generation Sequencing Study of 7 Cases.非小细胞肺癌伴透明细胞特征和 FGFR3::TACC3 基因重排:7 例的临床病理和下一代测序研究。
Am J Surg Pathol. 2024 Mar 1;48(3):284-291. doi: 10.1097/PAS.0000000000002167. Epub 2023 Dec 12.
2
Signet-Ring Cell Squamous Cell Carcinoma: A Biphenotypic Neoplasm of the Gastro-Esophageal Junction with Uncertain Biological Potential: Case Report and Literature Review.印戒细胞-鳞状细胞癌:胃食管交界处具有不确定生物学潜能的双表型肿瘤:病例报告及文献复习。
Int J Mol Sci. 2023 May 31;24(11):9535. doi: 10.3390/ijms24119535.
3
Successful Treatment and Retreatment With Erdafitinib for a Patient With Fusion Squamous NSCLC: A Case Report.
厄达替尼成功治疗和再治疗一例伴有 融合鳞状非小细胞肺癌患者:病例报告
JTO Clin Res Rep. 2023 Mar 30;4(5):100511. doi: 10.1016/j.jtocrr.2023.100511. eCollection 2023 May.
4
FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma.成纤维细胞生长因子受体 3 融合基因及其在人胶质母细胞瘤中的临床意义。
Int J Mol Sci. 2022 Aug 4;23(15):8675. doi: 10.3390/ijms23158675.
5
Uncontrollable Hemoptysis owing to Pseudoangiosarcomatous Carcinoma of the Lung.肺假性血管肉瘤所致难以控制的咯血
Am J Respir Crit Care Med. 2021 Jul 1;204(1):e1-e2. doi: 10.1164/rccm.202004-1307IM.
6
Emerging oncogenic fusions other than , , , and in NSCLC and the role of fusions as resistance mechanisms to targeted therapy.非 、 、 及 之外的非小细胞肺癌(NSCLC)中新兴的致癌融合基因以及融合基因作为靶向治疗耐药机制的作用
Transl Lung Cancer Res. 2020 Dec;9(6):2618-2628. doi: 10.21037/tlcr-20-186.
7
Erdafitinib Overcomes FGFR3-TACC3-Mediated Resistance to Osimertinib.厄达替尼克服FGFR3-TACC3介导的对奥希替尼的耐药性。
J Thorac Oncol. 2020 Sep;15(9):e154-e156. doi: 10.1016/j.jtho.2019.12.132.
8
Pulmonary Acantholytic Squamous Cell Carcinoma Mimicking Lepidic Pattern Adenocarcinoma.酷似鳞屑样模式腺癌的肺棘层松解性鳞状细胞癌
Turk Patoloji Derg. 2021;37(1):89-91. doi: 10.5146/tjpath.2019.01486.
9
Signet-Ring Cell Morphotype in Lung Carcinoma.肺癌中的印戒细胞形态型
Turk Patoloji Derg. 2020;36(3):275-276. doi: 10.5146/tjpath.2019.01475.
10
Clinical Presentation and Treatment Options for Clear Cell Lung Cancer: University of Cincinnati A Case Series and Literature Review of Clear Cell Lung Cancer.透明细胞肺癌的临床表现与治疗选择:辛辛那提大学透明细胞肺癌病例系列及文献综述
Asian Pac J Cancer Prev. 2018 Sep 26;19(9):2373-2376. doi: 10.22034/APJCP.2018.19.9.2373.